Jefferies Group LLC reissued their hold rating on shares of Henry Schein, Inc. (NASDAQ:HSIC) in a report published on Friday, July 21st. Jefferies Group LLC currently has a $177.00 target price on the stock.
Several other research firms have also weighed in on HSIC. Piper Jaffray Companies began coverage on shares of Henry Schein in a research note on Monday, June 12th. They set a neutral rating and a $200.00 target price for the company. Zacks Investment Research lowered shares of Henry Schein from a buy rating to a hold rating in a research report on Friday, June 23rd. Credit Suisse Group restated a hold rating and set a $160.00 price target on shares of Henry Schein in a research report on Thursday, July 13th. Stifel Nicolaus restated a hold rating on shares of Henry Schein in a research report on Thursday, July 6th. Finally, Barrington Research upped their price objective on shares of Henry Schein from $196.00 to $198.00 and gave the stock an outperform rating in a report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company’s stock. Henry Schein presently has an average rating of Hold and a consensus target price of $185.56.
Shares of Henry Schein (NASDAQ:HSIC) traded down 0.07% during mid-day trading on Friday, reaching $169.49. 525,408 shares of the company’s stock traded hands. The company’s 50-day moving average price is $179.49 and its 200-day moving average price is $175.49. Henry Schein has a 12-month low of $146.23 and a 12-month high of $186.99. The stock has a market capitalization of $13.40 billion, a PE ratio of 24.77 and a beta of 1.09. Henry Schein shares are going to split on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly minted shares will be payable to shareholders after the market closes on Thursday, September 14th.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.02. The firm had revenue of $3.06 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.64 earnings per share. Analysts anticipate that Henry Schein will post $7.27 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank increased its position in shares of Henry Schein by 25.7% in the second quarter. Toronto Dominion Bank now owns 26,872 shares of the company’s stock valued at $4,917,000 after buying an additional 5,487 shares during the period. WINTON GROUP Ltd boosted its stake in Henry Schein by 14.9% in the second quarter. WINTON GROUP Ltd now owns 11,297 shares of the company’s stock valued at $2,068,000 after buying an additional 1,465 shares in the last quarter. Colony Group LLC boosted its stake in Henry Schein by 1.3% in the second quarter. Colony Group LLC now owns 12,734 shares of the company’s stock valued at $2,331,000 after buying an additional 158 shares in the last quarter. Verition Fund Management LLC boosted its stake in Henry Schein by 130.7% in the second quarter. Verition Fund Management LLC now owns 4,152 shares of the company’s stock valued at $760,000 after buying an additional 2,352 shares in the last quarter. Finally, Nomura Holdings Inc. boosted its stake in Henry Schein by 89.4% in the second quarter. Nomura Holdings Inc. now owns 8,480 shares of the company’s stock valued at $1,553,000 after buying an additional 4,003 shares in the last quarter. Institutional investors own 90.60% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.